PYPD.US PolyPid

Healthcare Biotechnology USA Stocks
6.54 USD
Close of Nov 18, 2026
3.50 7.15
Market cap
USD 138M
P/E
-
P/B
33.31x
ROE
-729.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is PYPD.US undervalued?

Graham number

The Graham number of PolyPid cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

PolyPid fundamental analysis

No fundamental analysis for PolyPid yet.

PolyPid stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About PolyPid

PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The company is also developing OncoPL…

Full company profile